Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2001

View Archived Issues

Hollis-Eden receives approval to begin U.S. clinical trials with HE-2200

Enrollment completed in phase III clinical trial of T-20

Glycogen synthase 3 as a novel therapeutic target in type 2 diabetes

U.S. and French researchers investigate novel peptide vectors for gene, protein delivery

Potent analogues of hPTH and hPTHrP with bone anabolic effects

Gene and cell cycle effects elucidated for NB-1011

Orphan Medical receives approvable letter for Xyrem from FDA

Microbiological efficacy and safety of oritavancin in Gram-positive bacteremia

Nippon Shinyaku to market and distribute DepoCyt in Japan

Nexell submits IND for blood stem cell therapy as treatment of CGD

Aspirin-like compound exerts promising anti-HIV activity via a novel mechanism of action

Insulin sensitization with rosiglitazone may have numerous beneficial effects

Cyberonics launches VNS therapy for depression in Europe

Company begins phase I evaluation of XTL-002 for treatment of HCV

Schering-Plough seeks FDA approval for new formulation of PEG-Intron

Preliminary clinical results reported for Durect's Chronogesic

Old drug for diabetic neuropathy may be useful in migraine prophylaxis

PowderJect acquires SBL Vaccin

New LTB4 antagonists designed at Lilly for inflammation

Inhibitors of phosphodiesterase, TNF-alpha production and their use described by Merck

Cytovia presents new series of caspase activators and apoptosis inducers

Ortho-McNeil describes novel inflammatory cytokine inhibitors

Thrombopoietin mimetics in development at GSK

New NAALADase inhibitors from Guilford protect against cerebral ischemic insult

Neurogen's benzodiazepine-site ligands particularly useful for Rx of CNS disorders

Celgene team patents inhibitors of PDE4, TNF-alpha production and NF-kB activation

Xanthine-based adenosine receptor antagonists with particular utility in heart and renal failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...